retatrutide ly3437943 parkinson's disease clinical trial nct The NADPARK study: A randomized phase I of nicotinamide riboside supplementation in Current Therapies in Trials – Triple agonists of GIP, GLP-1,
Pay in 4 interest-free payments of $6.11 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5






















